https://ir.ataibeckley.com/news-releases/news...nt-effects
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression
https://journals.sagepub.com/doi/10.1177/02698811261420087